GIS vs NKTR · P/E 8.2, rev $18.42B vs rev $21.0M
General Mills Inc (GIS) versus Nektar Therapeutics (NKTR) — a side-by-side from cached financials, not a winner call.
General Mills Inc (GIS) is a packaged foods company listed on NYSE.
Nektar Therapeutics (NKTR) is a biotechnology company listed on US.
Latest reported GIS revenue for 2026-05-31 was $18.42B. Net income was -$87.6M. Revenue was up 304.4% from 2025-05-25 to 2026-05-31. GIS currently screens at market cap $17.80B and trailing P/E 8.2.
Latest reported NKTR revenue for 2026-06-30 was $21.0M. Net income was -$85.5M. Revenue was up 93.3% from 2026-03-31 to 2026-06-30. NKTR currently screens at market cap $307.2M.
GIS currently screens at market cap $17.80B and trailing P/E 8.2. NKTR currently screens at market cap $307.2M.
Not investment advice. Open the GIS and NKTR stock pages for the full models.
Not investment advice.